NMRD
vs
S&P 500
NMRD
S&P 500
Over the past 12 months, NMRD has underperformed S&P 500, delivering a return of -50% compared to the S&P 500's +14% growth.
Stocks Performance
NMRD vs S&P 500
Performance Gap
NMRD vs S&P 500
Performance By Year
NMRD vs S&P 500
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Nemaura Medical Inc
Glance View
Nemaura Medical, Inc. operates as a holding company. The company is headquartered in New York City, New York and currently employs 25 full-time employees. The company went IPO on 2014-11-04. The firm is focused on developing sugarBEAT, which is a non-invasive, glucose monitoring system, for use by persons with Type I and Type II diabetes and used to screen pre-diabetic patients. SugarBEAT consists of disposable adhesive skin-patch containing a sensor, which is connected to a rechargeable wireless transmitter.The SugarBEAT works by extracting glucose from the skin into a chamber in the patch that is in direct contact with an electrode-based sensor .The sensor takes a measurement of the glucose reading every five minutes and sends the data by low energy blue tooth to a smart device such as mobile phone (both android and iOS).The data is recorded on the app and can be viewed in real time as well as storing all historic data for later evaluation as desired. The firm's subsidiaries include Region Green Limited.